Haleon plc (LON:HLN - Get Free Report) announced a dividend on Thursday, February 27th, DividendData.Co.Uk reports. Shareholders of record on Thursday, April 24th will be paid a dividend of GBX 4.60 ($0.06) per share on Thursday, June 5th. This represents a yield of 1.18%. The ex-dividend date is Thursday, April 24th. This is a 130.0% increase from Haleon's previous dividend of $2.00. The official announcement can be accessed at this link.
Haleon Stock Performance
Shares of LON HLN traded up GBX 1.15 ($0.02) during midday trading on Friday, reaching GBX 377.75 ($5.03). 48,030,980 shares of the stock were exchanged, compared to its average volume of 26,987,539. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The firm has a market cap of £34.09 billion, a price-to-earnings ratio of 31.77, a PEG ratio of 1.49 and a beta of 0.19. The firm has a 50-day simple moving average of GBX 386.42 and a two-hundred day simple moving average of GBX 379.65. Haleon has a twelve month low of GBX 319.84 ($4.26) and a twelve month high of GBX 417.70 ($5.56).
Haleon (LON:HLN - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.21) EPS for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. As a group, analysts anticipate that Haleon will post 19.5033282 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank lifted their target price on shares of Haleon from GBX 456 ($6.07) to GBX 457 ($6.09) and gave the company a "buy" rating in a report on Friday, February 28th.
Get Our Latest Research Report on Haleon
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.
See Also

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.